Colorectal NeoplasmsNCT05069571
Endoangel Withdrawal Overspeed Analysis
An observational study of Colorectal Neoplasms, run by Renmin Hospital of Wuhan University at 1 site in China.
Trial summary
Exploring the relationship between the percentage of overspeed of colonoscopy withdrawal and the rate of adenoma detection. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colorectal Neoplasms
- What is being tested?
- Endoangel
- How many people
- 1,210 participants
- Where
- 1 siteChina
- Study dates
- 1 Mar 2020to 1 Feb 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients need to receive the colonoscopy examination.
Who may be able to join
- Males or females who are over 18 years old (inclusive);
- Enteroscopy and related examinations are needed to further clarify the characteristics of digestive tract diseases;
- Able to read, understand and sign the informed consent form;
- The researcher believes that the subject can understand the process of the clinical research, is willing and able to complete all the research procedures and follow-up visits, and cooperate with the research procedures.
Who cannot join
- Participated in other clinical trials, signed an informed consent form and within the follow-up period of other clinical trials;
- Abuse of drugs or alcohol or mental disorders in the last 5 years;
- Women during pregnancy or breastfeeding;
- Subjects with previous history of bowel surgery;
- The investigator believes that the subject is not suitable for enteroscopy and related examinations;
- The investigator believes that the subject is not suitable for high-risk diseases or other special circumstances to participate in clinical trials.
Show all 10Show fewer
- Patients with gastrointestinal bleeding;
- Known or highly suspected allergy to any ingredient of bowel cleansing agent;
- Restricted activities or any mental or physical condition impairs their ability to drink intestinal cleansing preparations;
- Known or suspected intestinal obstruction or perforation, toxic megacolon, most colectomy, heart failure (grade III or IV), severe cardiovascular disease, severe liver failure or end, renal insufficiency, etc.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Renmin Hospital of Wuhan University
Wuhan, Hubei, 430060
Honggang Yu, Doctor
About this study
Official title: Explore the Relationship Between the Percentage of Overspeed of Colonoscopy Withdrawal and the Rate of Adenoma Detection:a Prospective、Multicenter、Observational Study
Exploring the relationship between the percentage of overspeed of colonoscopy withdrawal and the rate of adenoma detection.
- Conditions
- Colorectal Neoplasms
- Being tested
- Endoangel
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EndoangelOther
Collecting the colonoscopy videos and analyzing the correlation between withdrawal overspeed proportion and adenoma detection rate.
What is being measured
The primary outcome is the main question the study is designed to answer.
Adenoma detection rate
Measured: 3 months
Secondary outcomes (1)
Proportion of withdrawal overspeed
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2021
- Study start1 Mar 2020
- Primary completion1 Nov 2021 (estimated)
- Study completion1 Feb 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Prospective
- Enrolment
- 1,210 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Renmin Hospital of Wuhan University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05069571
- Sponsor's protocol ID
- EA-21-009
- Status last verified
- Sep 2021
- First submitted
- 24 Sep 2021
- Last updated
- 6 Oct 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Explore the Relationship Between the Percentage of Overspeed of Colonoscopy Withdrawal and the Rate of Adenoma Detection:a Prospective、Multicenter、Observational Study
- ClinicalTrials.gov ID
- NCT05069571
- Acronym / sponsor ID
- EA-21-009
- Conditions
- Colorectal Neoplasms
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,210 participants (estimated)
- Lead sponsor
- Renmin Hospital of Wuhan UniversityUniversity, hospital or other
- Study start
- 1 Mar 2020 (actual)
- Primary completion
- 1 Nov 2021 (estimated)
- Study completion
- 1 Feb 2022 (estimated)
- First posted
- 6 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Exploring the relationship between the percentage of overspeed of colonoscopy withdrawal and the rate of adenoma detection.
Study design
- Observational model
- Case crossover
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients need to receive the colonoscopy examination.
Key inclusion criteria (4 listed)
- Males or females who are over 18 years old (inclusive);
- Enteroscopy and related examinations are needed to further clarify the characteristics of digestive tract diseases;
- Able to read, understand and sign the informed consent form;
- The researcher believes that the subject can understand the process of the clinical research, is willing and able to complete all the research procedures and follow-up visits, and cooperate with the research procedures.
Key exclusion criteria (10 listed)
- Participated in other clinical trials, signed an informed consent form and within the follow-up period of other clinical trials;
- Abuse of drugs or alcohol or mental disorders in the last 5 years;
- Women during pregnancy or breastfeeding;
- Subjects with previous history of bowel surgery;
- The investigator believes that the subject is not suitable for enteroscopy and related examinations;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EndoangelCollecting the colonoscopy videos and analyzing the correlation between withdrawal overspeed proportion and adenoma detection rate. | Other | – |
Primary outcome
Adenoma detection rate
Time frame: 3 months
1 secondary outcome
Proportion of withdrawal overspeed
Time frame: 3 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Colorectal Neoplasms
RecruitingPhase 1/2
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Colorectal Cancer
RecruitingPhase 1
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
Phase 1, SAR445877
Recruiting
Addressing Disparities in Colorectal Cancer Screening in Black and Underserved Phoenix Communities
Colorectal Carcinoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruiting
Smartphone-enabled Hybrid Identification of Early CoLorectal Disease Using Blood-Based Cancer Testing Across TeXas
Colorectal Cancer (CRC) Screening
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Neoplasms, run by Renmin Hospital of Wuhan University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Honggang Yu, Doctor (13871281899, yuhonggang@whu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Adenoma detection rate (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2021; AzTrials last refreshed its copy on 3 Nov 2026.